Beyond Transparency: Your 2027 Roadmap for PBM Evaluation

With rising drug costs, PBM transparency is just the start. This roadmap helps benefits advisors evaluate PBMs on what truly matters: effective cost control, waste management, and strategic decision-making for 2027 and beyond.

As 2027 approaches, rising prescription drug costs are putting immense pressure on employers. While transparency in Pharmacy Benefits Managers (PBMs) is a critical first step, it is no longer enough to control spend. A transparent model can still produce high costs if it lacks clinical discipline and strategic execution.

This roadmap provides benefits advisors with a new framework to guide clients toward better outcomes. It moves the conversation from "How transparent is this model?" to "How well does this model control long-term costs and protect members?"

Download this guide and you'll learn:

The five essential criteria for evaluating PBMs beyond surface-level transparency
How to assess clinical management as the primary lever for controlling waste
Strategies for executing a disciplined lowest net cost approach
How to turn PBM data into actionable insights that drive savings
Why flexible plan design is essential for meeting unique client goals
Offered Free by: Illuminate Rx

Please fill out the form below to access the content:

First Name

Last Name

Business Email

Phone Number

Job Title

Company Name

State

Country

Do you or your organization work with groups of the following size?

By submitting this content request, I have legitimate interest in the content and agree that Illuminate Rx, their partners, and the creators of any other content I have selected may contact me regarding news, products, and services that may be of interest to me.